Lundbeck is a global pharmaceutical company highly
committed to improving the quality of life of people living with brain
diseases. For this purpose, Lundbeck is engaged in the research, development,
manufacturing, marketing and sale of pharmaceuticals across the world. The
company’s products are targeted at the disease areas within psychiatry and
Today, millions of people live with brain diseases globally. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives.
As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovative therapeutics.
Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with brain diseases. We are specialists in our area and have research facilities in Denmark and California. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions.
Lundbeck markets a number of different pharmaceuticals for the treatment of brain diseases. The most recently launched compounds include: Rexulti® (depression and schizophrenia), Brintellix® (depression), Abilify Maintena® (schizophrenia) and Vyepti® (migraine).